Charles River Laboratories International (NYSE:CRL) EVP Shannon Parisotto Sells 3,714 Shares of Stock

Charles River Laboratories International, Inc. (NYSE:CRL) EVP Shannon Parisotto sold 3,714 shares of the stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $279.66, for a total value of $1,038,657.24. Following the completion of the transaction, the executive vice president directly owned 4,807 shares of the company’s stock, valued at approximately $1,344,325.62. This represents a 43.59% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Charles River Laboratories International Trading Down 0.9%

Shares of CRL stock opened at $281.78 on Friday. Charles River Laboratories International, Inc. has a fifty-two week low of $144.26 and a fifty-two week high of $288.02. The company has a debt-to-equity ratio of 0.92, a quick ratio of 1.04 and a current ratio of 1.35. The stock’s fifty day moving average is $222.90 and its two-hundred day moving average is $190.70. The firm has a market capitalization of $13.45 billion, a P/E ratio of -58.10, a PEG ratio of 2.95 and a beta of 1.38.

Charles River Laboratories International (NYSE:CRL) last released its earnings results on Wednesday, August 5th. The medical research company reported $3.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.77 by $0.25. The business had revenue of $1 billion during the quarter, compared to analyst estimates of $980.53 million. Charles River Laboratories International had a negative net margin of 5.96% and a positive return on equity of 15.75%. The company’s revenue for the quarter was down 2.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $3.12 earnings per share. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. Research analysts expect that Charles River Laboratories International, Inc. will post 11.35 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have commented on the stock. Morgan Stanley increased their price objective on shares of Charles River Laboratories International from $260.00 to $300.00 and gave the company an “overweight” rating in a report on Friday, August 7th. Citigroup restated a “buy” rating on shares of Charles River Laboratories International in a research report on Wednesday, July 8th. Piper Sandler set a $300.00 price target on Charles River Laboratories International in a report on Monday. Mizuho set a $264.00 price objective on Charles River Laboratories International in a research report on Monday. Finally, Robert W. Baird set a $291.00 price objective on Charles River Laboratories International in a research note on Thursday, August 6th. Twelve equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Charles River Laboratories International presently has a consensus rating of “Moderate Buy” and a consensus price target of $255.65.

Institutional Trading of Charles River Laboratories International

Several hedge funds have recently made changes to their positions in CRL. Cardinal Capital Management increased its holdings in shares of Charles River Laboratories International by 0.6% during the 4th quarter. Cardinal Capital Management now owns 10,928 shares of the medical research company’s stock worth $2,180,000 after buying an additional 62 shares during the last quarter. Asset Management One Co. Ltd. lifted its holdings in Charles River Laboratories International by 4.0% in the fourth quarter. Asset Management One Co. Ltd. now owns 1,847 shares of the medical research company’s stock valued at $375,000 after acquiring an additional 71 shares during the last quarter. Glenmede Trust Co. NA lifted its holdings in Charles River Laboratories International by 2.8% in the first quarter. Glenmede Trust Co. NA now owns 2,706 shares of the medical research company’s stock valued at $467,000 after acquiring an additional 73 shares during the last quarter. Mercer Global Advisors Inc. ADV grew its position in Charles River Laboratories International by 1.3% in the fourth quarter. Mercer Global Advisors Inc. ADV now owns 6,316 shares of the medical research company’s stock worth $1,260,000 after acquiring an additional 80 shares during the period. Finally, Advisory Services Network LLC grew its position in Charles River Laboratories International by 2.6% in the third quarter. Advisory Services Network LLC now owns 3,226 shares of the medical research company’s stock worth $505,000 after acquiring an additional 83 shares during the period. Hedge funds and other institutional investors own 98.91% of the company’s stock.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.